Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-05-24
2005-05-24
Barts, Samuel (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S047000, C514S048000, C514S049000, C514S050000, C514S052000, C514S081000, C536S026230, C536S026260, C544S264000, C544S265000
Reexamination Certificate
active
06897201
ABSTRACT:
The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a nucleoside 5′-pyrophosphate pyranoside or analogue, which is defined by general Formula I. The method of the present invention is useful in the treatment or prevention of ocular hypertension, such as found in glaucoma, including primary and secondary glaucoma. The method can be used alone to reduce intraocular pressure. The method can also be used in conjunction with another therapeutic agent or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic effect of reducing the intraocular pressure. The present invention also provides a novel composition comprising a nucleoside 5′-pyrophosphate pyranoside or analogues.
REFERENCES:
patent: 5219849 (1993-06-01), Lotti et al.
patent: 5545626 (1996-08-01), Stein et al.
patent: 5654285 (1997-08-01), Ingall et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 5955447 (1999-09-01), Ingall et al.
patent: 6166022 (2000-12-01), Brown et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: WO 9217488 (1992-10-01), None
patent: WO 9418216 (1994-08-01), None
patent: WO 9703084 (1997-01-01), None
patent: WO 9828300 (1998-07-01), None
patent: WO 0003741 (2000-01-01), None
patent: WO 0033080 (2000-06-01), None
patent: WO 0034283 (2000-06-01), None
patent: WO 0119826 (2001-03-01), None
patent: WO 0136421 (2001-05-01), None
patent: WO 0139781 (2001-06-01), None
patent: PCTUS03/06685 (2003-02-01), None
Chambers, et al., “A G Protein-coupled Receptor for UDP-glucose,”J. Biol. Chem., 275:10767-10771 (2000).
Crawford, et al., “Agonist-induced Ca2+mobilization in cultured bovine and human corneal endothelial cells,”Current Eye Res., 12(4): 303-311 (1993).
Jumblatt and Jumblatt, “Regulation of Ocular Mucin Secretion by P2Y2Nucleotide Receptors in Rabbit and Human Conjunctive,”Exp. Eye Res., 67(3):341-6 (1998).
Peral, et al., “Effects of diadenosine polyphosphates on intraocular pressure and pupil size in New Zealand rabbits,”Investig. Opthalmol. Vis. Science, 41:S255 (2000).
Pintor, et al., “Effect of ATP and adenine nucleotides on Intraocular pressure in New Zealand rabbits,”Investig. Opthalmol. Vis. Science, 41:S255 (2000).
Roetth, “Lenticular Opacities in Glaucoma Patients Recieving Echothiophate Iodide Therapy,”J.A.M.A., 195:644-666 (1966).
Simon, et al., “Convenient Syntheses of Cytidine 5′-Triphosphate, Guanosine 5′-Triphosphate, and Uridine 5′-Triphosphate and Their Use in the Preparation of UDP-glucose, UDP-gluconic Acid, and GDP-mannose,”J. Org. Chem., 55:1834-1841 (1990).
Wax and Coca-Prados, “Receptor-Mediated Phosphoinositride Hydrolysis in Human Ocular Ciliary Epithelial Cells,”Ivestig. Opthalmol. Vis. Science, 30(7):1675-1679 (1989).
Wax, et al., “Purinergic Receptors in Ocular Ciliary Epithelial Cells,”Exp. Eye Res., 57: 89-95 (1993).
Boyer José L.
Brown Edward G.
Plourde, Jr. Robert
Yerxa Benjamin R.
Barts Samuel
Howrey Simon Arnold and White
Inspire Pharmaceuticals Inc.
Kung Viola T.
Lewis Patrick
LandOfFree
Compositions and methods for the treatment of glaucoma or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of glaucoma or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of glaucoma or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3392794